Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

此申请是针对PA-20-272提交的 项目摘要 虽然几种创新和创造性的抗癌疗法已经显示出有希望的结果，但一个重要的 扩大它们的临床应用将需要合作努力来阐明耐药机制，利用 肿瘤敏感性，绘制癌症依赖图，发现新靶点，识别预测生物标志物，评估 联合疗法，并开发实时监测方法。利用尖端的多 纪律小组的方法，我们将支持NCI耐药性和敏感性网络(DRSN) 认识和对抗肿瘤耐药机制，开发肿瘤抗癌敏感性 治疗。我们的战略是成为管理、沟通、协作和分析中心，以 协调DRSN的全网络研究，重点减少领域专业知识的障碍，改进 DRSN调查人员的生产力，保持数据协调和整合的高标准， 设计和实施严格的分析策略，并培养协作和支持性 研究社区。 已经组建了一支经验丰富的多学科团队，以实现五个具体目标：第一，我们将 提供集中式管理基础设施以协调DRSN活动，其基础是 肿瘤学翻译网络数据管理与资源共享中心S 目前在NCI癌症保护伞下协调网络研究的运行基础设施 登月计划。第二，我们将积极推动DRSN，促进跨财团互动， 在那里我们将利用IOTN DMRC在跨月球拍摄方面的明显经验，并 生物导体数十年来在社区参与方面的记录。第三，我们将提供多学科 支持DRSN协作研究的专业知识，利用罗斯韦尔公园CCSG的四个共享 资源：生物统计学、生物信息学、数据库和生物仓库、生物分析、代谢组学和 药物动力学。我们的分析支持将配备专业的IT人员，并由 经验丰富的抗癌治疗研究团队。四是发展创新多元组学数据 整合方法，以增强DRSN的研究能力，利用备受尊敬和高度 成功的生物导体项目。第五，我们将向更广泛的人传播在DRSN中开发的资源 社区，释放DRSN活动的全部潜力。综上所述，我们设想我们的CC，在近距离 与DRSN组件的协作将使我们能够进行高效和创新 翻译研究，以解决与抗癌治疗相关的显著未得到满足的需求，并满足 NCI癌症登月计划的期望和指导原则。

This application is being submitted in response to PA-20-272 Project Summary While several innovative and creative anti-cancer therapies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate resistance mechanisms, exploit tumor sensitivity, map cancer dependence, discover new targets, identify predictive biomarkers, evaluate combination therapies, and develop real-time monitoring approaches. Leveraging cutting-edge multi- disciplinary team approaches, we will support the NCI Drug Resistance and Sensitivity Network (DRSN) to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies. Our strategy is to serve as an administration, communication, collaboration and analysis hub to coordinate the DRSN’s network-wide studies, focusing on reducing barriers to domain expertise, improving the productivity of DRSN investigators, maintaining a high standard for data harmonization and integration, designing and implementing rigorous analytical strategies, and fostering a collaborative and supportive research community. An experienced, multidisciplinary team has been assembled to pursue five Specific Aims: First, we will provide a centralized administration infrastructure to coordinate DRSN activities, building upon the Immuno- Oncology Translational Network (IOTN) Data Management and Resource-sharing Center (DMRC)’s well- functioning infrastructure that currently coordinates network studies under the umbrella of the NCI Cancer Moonshot initiative. Second, we will actively promote the DRSN and foster trans-consortium interactions, where we will leverage the IOTN DMRC’s demonstrable experience in Cross-Moonshot outreach and Bioconductor’s decades-long record in community-wide engagement. Third, we will provide multidisciplinary expertise to support DRSN collaborative research, leveraging four of the Roswell Park CCSG’s shared resources: Biostatistics, Bioinformatics, Data Bank and BioRepository, Bioanalytics, Metabolomics & Pharmacokinetics. Our analytic support will be armed with professional IT staff and informed by an experienced anti-cancer therapeutic researcher team. Fourth, we will develop innovative multi-omics data integration methods to enhance DRSN’s research capacity, capitalizing on the well-respected and highly- successful Bioconductor project. Fifth, we will disseminate resources developed in the DRSN to the broader community, unleashing the full potential of DRSN activities. Taken together, we envision our CC, in close collaboration with the DRSN components, will allow us to conduct highly effective and innovative translational studies to address the significantly unmet needs related to anti-cancer therapeutics, and fulfill the expectations and guiding principles of NCI Cancer Moonshot initiative.